Overview

Major Pharmaceutical companies worldwide use our Fusion QbD® Software Platform (Fusion QbD) every day to successfully develop truly robust and transferrable methods, including enterprise deployments at more than half of the world’s largest pharmaceutical companies. In addition, regulatory agencies use Fusion QbD to modernize methods and to challenge robustness claims in Pharma company submittals!

Our proven capabilities are now available to you as a service!

S-Matrix Analytical Development Labs (ADL) takes a unique approach to method development:

♦ All work is done using Fusion QBD, which implements a Quality by Design (QbD) approach 100% aligned with regulatory guidances and expectations, and enables us to rapidly develop truly robust and transferrable methods.

[ICH Q2(R1), Q8(R2), Q9 – Q11] / [USP 〈1220〉, 〈1224 – 6〉]

♦ All work can be done using the Chromatography Data Software (CDS) you use in your labs:
Key Differentiators of our Service

♦ Define your Analytical Target Profile (ATP) – we work with you to define quantitative statements of your required method performance. The ATP is used to assess project progress, and is the basis of your verification and acceptance of the final delivered method.

Analytical Target Profile (ATP)
The concept of an ATP parallels the concept of a Quality Target Product Profile described and defined in ICH Q8. The ATP defines the requirements for the “product” of the test procedure, which in this case is the reportable result. Criteria defined in the ATP refer to the quality data attributes of the reportable result, i.e., accuracy and measurement uncertainty, which include all sources of variability, including precision. Identifying the output of the analytical procedure as the reportable result provides a target for development and helps to ensure the procedure is developed toward predetermined performance requirements that are directly linked to the quality of the data. In other words, the ATP defines the objective of the test and quality requirements, including the expected level of confidence, for the reportable result that allows the correct conclusion to be drawn regarding the attributes of the material that is being measured.

Proposed New USP General Chapter: The Analytical Procedure Lifecycle (1220)

♦ Integrate quantitative metrics of method robustness for all key performance characteristics – as specified in the ATP – into the method optimization work.

It should be noted that robustness is not listed in the [typical validation characteristics] table but should be considered at an appropriate stage in the development of the analytical procedure. ICH Q2(R1).

“Statistical treatments (e.g., Monte Carlo simulations) can help evaluate the effects of uncertainty.”
Points to Consider for Design Space – A Regulatory Perspective, Elaine Morefield, Ph.D. 2012 Annual Meeting, AAPS.

The FDA has stated that accepted process capability indices such as $C_p$, $C_{pk}$, $C_{pkm}$, and $C_{pkm}$ are also part of the QbD toolset.
US FDA, Quality by Design: Objectives, Benefits, and Challenges, Lawrence X. Yu, Ph.D. 2012 Annual Meeting, AAPS.
Execute the project according to formal Quality by Design principles, optimize the method in terms of mean (average) performance and method robustness, and formally establish the method’s Robust Design Space and Proven Acceptable Ranges (PARs) – referred to by Analytical QbD practitioners as the Method Operable Design Region - MODR.

**Design Space:**
The multidimensional combination and interaction of input variables (e.g., material attributes) and process parameters that have been demonstrated to provide assurance of quality. Working within the design space is not considered as a change. Movement out of the design space is considered to be a change and would normally initiate a regulatory postapproval change process. *ICH Q8(R2).*

Perform a full suite of validation experiments to verify the ultimate validatability of the method. These experiments include:

- System Suitability
- Filter Validation
- Sample Solution Stability
- Specificity
- Accuracy
- Linearity and Range
- Precision –
- Repeatability
- Intermediate Precision
- Detection Limit
- Quantitation Limit
- Robustness Verification

Fully document and report all data, work, and results.
Principal Investigator – Joseph A. Turpin

Professional Profile

- Over 35 years’ experience with chemical and pharmaceutical drug product and drug substance process analytical development.
- Expertise in design, development, implementation, and validation of laboratory informatics systems, including data acquisition systems, LIMS, Scientific Data Management Systems, and Electronic Laboratory Notebooks.
- Recognized leader in the development of QbD chromatography method development.
- Experienced with recruiting, management and development of scientific professionals.

Highlight of Technical Knowledge, Skills and Accomplishments

- Experienced with statistical methods, experimental design, and statistical quality control.
- Strong expertise in gas, liquid, and SFC chiral and achiral chromatography assay development.
- Experienced with qualitative and quantitative GC/MS and LC/MS analysis.
- Broad Analytical development experience. Commercialized products include: Evista®, Lorabid®, Alimta®, Cialis®, Comfortis®, Reconcile®, Trifexis®, Cheristin™.
- Current projects include QbD analytical development for drug substances and drug products.
- Leader in development of laboratory informatics solutions with involvement in high level design, implementation and management of LIMS, SDMS, e-Notebooks.
- Heavily involved in acquisition implementation of new technology for the past 35 years.

Summary of Work Experience

S-Matrix Corporation, Eureka, CA  
Feb, 2017-Present  
- Director, Chromatography Products and Services, S-Matrix Analytical Development Laboratories, Indianapolis, IN.

Eli Lilly and Company Indianapolis, IN  
1990 – 2017  
- Sr. Research Scientist, Elanco Animal Health Division of Eli Lilly and Company, Greenfield, IN, 2015-present.